摘要
目的观察体重指数对应用拉米夫定治疗的慢性乙型肝炎患者抗病毒疗效的影响。方法观察组36例体重指数〉28 kg/m2的慢性乙型肝炎患者,与对照组30例体重指数20～25 kg/m2慢性乙型肝炎患者,均应用拉米夫定100 mg每日一次治疗,分别比较治疗第12周、24周、48周时患者血清ALT、HBVDNA变化情况。结果治疗的第12周、24周、48周,观察组患者ALT复常率分别为11.1%、36.1%、63.9%,对照组患者ALT复常率分别为16.7%、40%、86.7%,48周时2组间比较差异有统计学意义,P〈0.05。观察组患者HBVDNA阴转率分别为8.3%、22.2%、33.3%,对照组患者HBVDNA阴转率分别为13.3%、30%、76.7%,48周时2组间比较差异有统计学意义,P〈0.05。观察组患者病毒学突破率分别为0/36、3/36、9/36,对照组患者病毒学突破率分别为0/30、0/30、2/30,48周时2组间比较差异有统计学意义,P〈0.05。结论体重指数不同可以影响慢性乙型肝炎患者对拉米夫定的敏感性及抗HBV疗效。
Objective To observe the impact of body mass index（BMI） on the curative efficacy of lamivudine in the treatment of anti-hepatitis B virus. Methods Observation group included 36 cases of chronic hepatitis B （CHB） with BMI more than 28 kg/m2 ,and the control group included 30 cases of CHB with BMI of 20 to 25 kg/m2. All patients were treated by lamivudine 100 mg once daily,the serum ALT and HBV DNA levels of both groups were tested at week 12,24 and 48. then the change condition of the patients. Results At 12,24 and 48 week, the rate of ALT normalization in the ob- servation group was 11.1% ,36.1% and 63.9% ,respectively,and in the control group was 16.7% ,40% and 86.7% , respectively, there was a significant difference at week 48 （P 〈 0. 05） ;while the rate of HBV I）NA negative conversion in the observation group was 8.3% ,22.2% ,33.3% ,respectively,and the control group was 13.3% ,30% ,76.7% ,respec- tively, there was a significant difference also at week 48 （ P 〈 0.05 ） ; while the rate of virologic breakthrough in the obser- vation group was 0/36,3/36 and 9/36, respectively,in the control group was 0/30,0/30 and 2/30, respectively, the sig- nificant difference was found at 48 weeks between the two groups （P 〈 0.05 ）. Conclusion The sensitivity of lamivudine and anti-HBV effect can be affected by BMI in patients with chronic hepatitis B.
出处
《中华全科医学》
2014年第12期1948-1949,1952,共3页
Chinese Journal of General Practice
关键词
体重指数
慢性乙型肝炎
拉米夫定
HBV
DNA
Body mass index
Chronic hepatitis B
Lamivudine
Hepatitis B virus （HBV） DNA
